Drug Trial Radar · NCT01426386
A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment
Last checked: Nov 19, 2026Latest source record: Nov 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
265
Actual
Start
Sep 2011
Primary completion
Apr 2012
Study completion Mar 2013
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 37 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.
Conditions
- Infertility
Interventions
FE 999049Drug
Gonal - FDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Oocytes RetrievedTime frame: Day of oocyte retrieval (up to Day 18 after start of stimulation)
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
UZ Brussel
Brussels, Belgium
UZ Gent
Ghent, Belgium
ICF CUBE
Prague, Czechia
Rigshospitalet
Copenhagen, Denmark
IU Dexeus
Barcelona, Spain
IVI Madrid
Madrid, Spain
IVI Sevilla
Seville, Spain
IVI Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.